{"title":"葡萄糖共转运蛋白2抑制剂钠在高血压中的作用","authors":"Zhitong Zhou, Daowen Wang, Junfang Wu","doi":"10.53941/ijddp.v1i1.175","DOIUrl":null,"url":null,"abstract":"Review\nRole of Sodium Glucose Cotransporter 2 Inhibitor in Hypertension\n\nZhitong Zhou, Dao Wen Wang, Junfang Wu *\n\n\nDivision of Cardiology, Department of Internal Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Hubei Key Laboratory of Genetics and Molecular Mechanisms of Cardiological Disorders, Wuhan 430030, China.\n* Correspondence: Junfang.wu@tjh.tjmu.edu.cn\n \n \nReceived: 17 October 2022\nAccepted: 15 November 2022\nPublished: 21 December 2022\n \n\nAbstract: Sodium glucose cotransporter 2 inhibitors (SGLT-2i) are a new class of antidiabetic drugs that act by inhibiting the reabsorption of glucose in the proximal renal tubule, which results in lowering the level of blood and urinary glucose. Besides the glucose-lowing effect, some clinical trials found the benefits of SGLT2i in treating heart failure with or without diabetes. In 2021, SGLT2i were recommended by the European Society of Cardiology in treating of heart failure. Compared to heart failure, hypertension is a common cardiovascular disease with an increasing prevalence globally. There is also clinical evidence indicating that SGLT2i can lower blood pressure. Here we focused on addressing the role of SGLT-2i in treating hypertension and its possible mechanism in this review.","PeriodicalId":94047,"journal":{"name":"International journal of drug discovery and pharmacology","volume":"19 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2022-12-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":"{\"title\":\"Role of Sodium Glucose Cotransporter 2 Inhibitor in Hypertension\",\"authors\":\"Zhitong Zhou, Daowen Wang, Junfang Wu\",\"doi\":\"10.53941/ijddp.v1i1.175\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Review\\nRole of Sodium Glucose Cotransporter 2 Inhibitor in Hypertension\\n\\nZhitong Zhou, Dao Wen Wang, Junfang Wu *\\n\\n\\nDivision of Cardiology, Department of Internal Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Hubei Key Laboratory of Genetics and Molecular Mechanisms of Cardiological Disorders, Wuhan 430030, China.\\n* Correspondence: Junfang.wu@tjh.tjmu.edu.cn\\n \\n \\nReceived: 17 October 2022\\nAccepted: 15 November 2022\\nPublished: 21 December 2022\\n \\n\\nAbstract: Sodium glucose cotransporter 2 inhibitors (SGLT-2i) are a new class of antidiabetic drugs that act by inhibiting the reabsorption of glucose in the proximal renal tubule, which results in lowering the level of blood and urinary glucose. Besides the glucose-lowing effect, some clinical trials found the benefits of SGLT2i in treating heart failure with or without diabetes. In 2021, SGLT2i were recommended by the European Society of Cardiology in treating of heart failure. Compared to heart failure, hypertension is a common cardiovascular disease with an increasing prevalence globally. There is also clinical evidence indicating that SGLT2i can lower blood pressure. Here we focused on addressing the role of SGLT-2i in treating hypertension and its possible mechanism in this review.\",\"PeriodicalId\":94047,\"journal\":{\"name\":\"International journal of drug discovery and pharmacology\",\"volume\":\"19 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-12-21\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International journal of drug discovery and pharmacology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.53941/ijddp.v1i1.175\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International journal of drug discovery and pharmacology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.53941/ijddp.v1i1.175","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Role of Sodium Glucose Cotransporter 2 Inhibitor in Hypertension
Review
Role of Sodium Glucose Cotransporter 2 Inhibitor in Hypertension
Zhitong Zhou, Dao Wen Wang, Junfang Wu *
Division of Cardiology, Department of Internal Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Hubei Key Laboratory of Genetics and Molecular Mechanisms of Cardiological Disorders, Wuhan 430030, China.
* Correspondence: Junfang.wu@tjh.tjmu.edu.cn
Received: 17 October 2022
Accepted: 15 November 2022
Published: 21 December 2022
Abstract: Sodium glucose cotransporter 2 inhibitors (SGLT-2i) are a new class of antidiabetic drugs that act by inhibiting the reabsorption of glucose in the proximal renal tubule, which results in lowering the level of blood and urinary glucose. Besides the glucose-lowing effect, some clinical trials found the benefits of SGLT2i in treating heart failure with or without diabetes. In 2021, SGLT2i were recommended by the European Society of Cardiology in treating of heart failure. Compared to heart failure, hypertension is a common cardiovascular disease with an increasing prevalence globally. There is also clinical evidence indicating that SGLT2i can lower blood pressure. Here we focused on addressing the role of SGLT-2i in treating hypertension and its possible mechanism in this review.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
